placebo + alendronate

This combination regimen refers to the active comparator arm used in a Phase 2 clinical trial (NCT06144125) led by Nitin Agarwal at the University of Pittsburgh. The regimen consists of a weekly oral dose of **alendronate** (70 mg) and a monthly subcutaneous injection of a **placebo** designed to mimic the appearance and administration of romosozumab. Alendronate is a nitrogen-containing bisphosphonate that acts as an antiresorptive agent by inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts, thereby reducing bone turnover and increasing bone mineral density. The placebo component is pharmacologically inactive and is utilized to maintain the double-blind, double-dummy study design. The trial specifically evaluates whether romosozumab is superior to standard-of-care alendronate in improving bone strength and surgical outcomes for postmenopausal women with osteoporosis undergoing lumbar spine surgery.

Brand names

Fosamax

Other names

Placebo Romosozumab + AlendronateAlendronate + Placebo